In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Are Rumors of TMR's Death Greatly Exaggerated?

Executive Summary

DIRECT, the first placebo-controlled trial of a laser myocardial revascularization technology, did not prove any benefit from the therapy, an announcement that has stirred a hornet's nest of controversy in the TMR/PMR industry. Laser companies and physicians who perform the procedures have been in damage control mode since the announcement. The event has exacerbated the challenges that laser companies were already facing in the early adoption phase of a new treatment paradigm. PLC Systems and Eclipse Surgical feel confident that their technologies are sufficiently different from that used in the DIRECT trial and are striving to reassure physicians, patients and investors. In its efforts to convince skeptical physicians or those put off by the DIRECT results, PLC is banking on its perfusion data and its positive 5-year results for its surgical TMR approach. Eclipse hopes positive results from its clinical trial will help it get approval for the first interventional approach.

You may also be interested in...

Are Placebo Trials a Wave of the Future in Medical Devices?

In the wake of a study (reported in the "The New England Journal of Medicine") that arthroscopic surgery in patients delivered no better results than did a placebo procedure, industry executives are asking, "What role should placebo trials play in assessing the clinical value of medical devices or device-driven procedures?

Putting Things in Place in TMR

Development in transmyocardial revascularization suggest this promising technology may be getting ready for a major run.

Cardiac Laser's Last Best Hope

Cardiac lasers have been long on promise but short on delivery. Now, a pair of new and unproven techniques with roots in reptile physiology--transmyocardial and percutaneous myocardial revascularization--are energizing the use of high-tech lasers in cor

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts